In keeping with Cathie Wood's style, these picks are riskier than average. Via her ARK Innovation ETF (ARKK 1.25%), portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and temperamental stocks, though investors are lured back time and time again because they offer the possibility of big returns in exchange for significant risks. Does it make sense to invest in these stoc ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned +3.5%, compared to the Zacks S&P 500 composite's +4.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 5%. The key question now is: What could be the stock's future direc ...

There are a handful of different factors that could buoy its stock. As its shareholders already know, CRISPR Therapeutics (CRSP -0.88%) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint blockbuster drugs, and plenty of financial flexibility, there's no shortage of reasons to buy the stock. But even for those who appreciate the company's merits, the picture is likely even sunnier than they realize. Here are three reasons why the sto ...

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of d ...

With a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (CRSP -1.28%) is making it a good time to be a shareholder. But could this biotech's halcyon days be so good that a $10,000 investment today could end up being worth millions of dollars? Although such returns may seem wild, history is full of many such wealth-generating events. Let's dive in and explore if investors can bank on CRISPR Therapeutics stock to generate ground- br ...

These biotech stocks have just launched their first products. The stock market is roaring higher, with the Nasdaq and S&P 500 recently extending gains to reach new record highs. But don't worry. It's not too late to get in on this market growth. The indexes confirmed their presence in a bull market earlier this year, but these phases of market optimism tend to last quite some time -- and history shows us they generally go on for much longer than bear markets. In a study spanning 1926 through 2017, the avera ...

In my view, Vertex and CRISPR Therapeutics are well-positioned to grab upwards of 20% of Casgevy's total addressable market. The therapy -- a one-time treatment that should provide patients with a functional cure -- costs $2.2 million per treatment in the U.S., so there is a multibillion-dollar opportunity here. Casgevy: The sky is the limit Developing gene-editing therapies is difficult, but commercializing them is its own challenge. To administer Casgevy, physicians first need to collect the patient's cel ...

业绩总结 - CRISPR Therapeutics AG 去年与合作伙伴 Vertex 公司获得了 CASGEVY 的批准，这款产品在商业上取得了良好的开端[2] - CRISPR Therapeutics AG 目前在临床阶段有五个项目，涵盖了肿瘤学、自身免疫疾病、心血管疾病、罕见病和糖尿病等领域[3] - CRISPR Therapeutics AG 计划在未来五年内每年至少推出两个新项目，展示了公司科学引擎的高效生产力[5] 新产品和新技术研发 - CRISPR Therapeutics AG 的 CAR T 疗法在肿瘤学和自身免疫疾病领域表现出色，展示了潜在的治疗优势[10] - CRISPR Therapeutics AG 的 ALAS1 项目针对急性肝性卟啉病，展示了在模型中的潜在疗效[23] - CRISPR Therapeutics AG 的 AGT 项目和 ALAS1 项目进一步拓展了公司的疾病治疗范围，覆盖了常见和罕见疾病[13] - CRISPR Therapeutics AG 的新项目 340 针对高血压患者，展示了潜在的降压效果，为治疗难治性高血压和抗药性高血压提供新途径[18] - CRISPR Therapeutics AG 的 Allogeneic CAR T 项目展示了在自身免疫疾病领域的潜在应用，为持久缓解提供可能性[28] 市场扩张和并购 - CASGEVY 的成功推出对整个行业具有标志性意义，受到广泛关注，预计通过有针对性的条件化将市场扩大至少三倍以上[6] 其他新策略和有价值的信息 - 公司在自身的研究中发现，使用lenti治疗自身免疫疾病存在二次恶性肿瘤的风险，因此需要更严格的审查[30] - 公司认为自身的CAR Ts和NK细胞比其他同类产品更具潜力和效力[30] - 公司在糖尿病领域有三个并行项目，其中CTX211是世界首个进入人体试验的编辑干细胞衍生产品[33]

And that's OK -- at least according to Oppenheimer analyst Jay Olson, who on Friday lowered his price target on CRISPR stock to $95 a share, but maintained an outperform rating on the stock. How much would you pay for a stock that might earn $25 a year in six years? CRISPR Therapeutics (CRSP 2.26%) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 2023, CRISPR's revenue plummeted 99.5% year over ...

These healthcare stocks offer completely different approaches to long-term investment gains. Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon. Moreover, there's a wide variety of healthcare companies, making it an attractive sector for any type of investor. Consider how this value stock and this growth stock below might enhance your portfolio. 1. Pfizer Pfizer (PFE -0 ...